RU2771280C2 - Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма - Google Patents

Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма Download PDF

Info

Publication number
RU2771280C2
RU2771280C2 RU2019103883A RU2019103883A RU2771280C2 RU 2771280 C2 RU2771280 C2 RU 2771280C2 RU 2019103883 A RU2019103883 A RU 2019103883A RU 2019103883 A RU2019103883 A RU 2019103883A RU 2771280 C2 RU2771280 C2 RU 2771280C2
Authority
RU
Russia
Prior art keywords
methyl
oxadiazol
amino
carboxylate
methylpiperazine
Prior art date
Application number
RU2019103883A
Other languages
English (en)
Russian (ru)
Other versions
RU2019103883A (ru
RU2019103883A3 (cg-RX-API-DMAC7.html
Inventor
Алан Стюарт ЙЕССИМАН
Патрик Стефен Джонсон
Кристоффер МОНССОН
Мортен Дахль СОРЕНСЕН
Original Assignee
Лео Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лео Фарма А/С filed Critical Лео Фарма А/С
Publication of RU2019103883A publication Critical patent/RU2019103883A/ru
Publication of RU2019103883A3 publication Critical patent/RU2019103883A3/ru
Application granted granted Critical
Publication of RU2771280C2 publication Critical patent/RU2771280C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
RU2019103883A 2016-07-13 2017-07-11 Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма RU2771280C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16020268 2016-07-13
EP16020268.5 2016-07-13
PCT/EP2017/067390 WO2018011201A1 (en) 2016-07-13 2017-07-11 Heteroaromatic modulators of the retinoid-related orphan receptor gamma

Publications (3)

Publication Number Publication Date
RU2019103883A RU2019103883A (ru) 2020-08-13
RU2019103883A3 RU2019103883A3 (cg-RX-API-DMAC7.html) 2020-09-23
RU2771280C2 true RU2771280C2 (ru) 2022-04-29

Family

ID=56511303

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019103883A RU2771280C2 (ru) 2016-07-13 2017-07-11 Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма

Country Status (21)

Country Link
US (2) US10662181B2 (cg-RX-API-DMAC7.html)
EP (1) EP3484880B1 (cg-RX-API-DMAC7.html)
JP (1) JP7016344B2 (cg-RX-API-DMAC7.html)
KR (1) KR102490140B1 (cg-RX-API-DMAC7.html)
CN (1) CN109476653B (cg-RX-API-DMAC7.html)
AU (1) AU2017294969B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019000486A2 (cg-RX-API-DMAC7.html)
CA (1) CA3030370A1 (cg-RX-API-DMAC7.html)
DK (1) DK3484880T3 (cg-RX-API-DMAC7.html)
ES (1) ES2834009T3 (cg-RX-API-DMAC7.html)
IL (1) IL264141B (cg-RX-API-DMAC7.html)
MX (1) MX383770B (cg-RX-API-DMAC7.html)
MY (1) MY196990A (cg-RX-API-DMAC7.html)
PL (1) PL3484880T3 (cg-RX-API-DMAC7.html)
PT (1) PT3484880T (cg-RX-API-DMAC7.html)
RU (1) RU2771280C2 (cg-RX-API-DMAC7.html)
SA (1) SA519400868B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201811107WA (cg-RX-API-DMAC7.html)
UA (1) UA123330C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018011201A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201808436B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2771280C2 (ru) * 2016-07-13 2022-04-29 Лео Фарма А/С Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма
CN111825654A (zh) * 2019-04-19 2020-10-27 北京酷瓴生物技术有限公司 苯甲烯哌啶衍生物及其制备方法、中间体和用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1542415A3 (ru) * 1983-06-16 1990-02-07 Берингер Ингельгейм Лтд (Фирма) Способ получени пиперазинилсодержащих производных мочевины или тиомочевины или их солей с сол ной кислотой
RU2445308C2 (ru) * 2005-04-04 2012-03-20 Аб Сьянс Замещенные производные оксазола и их применение в качестве ингибиторов тирозинкиназы
WO2014086894A1 (en) * 2012-12-06 2014-06-12 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
WO2015180613A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2015180614A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2015180612A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
EA023638B1 (ru) * 2011-04-12 2016-06-30 Биопроже Производные 1-{4-(5-арил-[1,2,4]-оксадиазол-3-ил)бензил}пиперидин-4-илкарбоновой кислоты в качестве агонистов s1p1 рецепторов

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073612A2 (en) 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
FR2879381B1 (fr) 2004-12-15 2008-12-26 Thales Sa Systeme de distribution quantique de cle de cryptage a variables continues
WO2015067575A1 (en) * 2013-11-05 2015-05-14 F. Hoffmann-La Roche Ag 5,6,7,8-tetrahydro-5,8-methanocinnoline derivatives as rorc modulators for the treatment of autoimmune diseases
RU2771280C2 (ru) * 2016-07-13 2022-04-29 Лео Фарма А/С Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1542415A3 (ru) * 1983-06-16 1990-02-07 Берингер Ингельгейм Лтд (Фирма) Способ получени пиперазинилсодержащих производных мочевины или тиомочевины или их солей с сол ной кислотой
RU2445308C2 (ru) * 2005-04-04 2012-03-20 Аб Сьянс Замещенные производные оксазола и их применение в качестве ингибиторов тирозинкиназы
EA023638B1 (ru) * 2011-04-12 2016-06-30 Биопроже Производные 1-{4-(5-арил-[1,2,4]-оксадиазол-3-ил)бензил}пиперидин-4-илкарбоновой кислоты в качестве агонистов s1p1 рецепторов
WO2014086894A1 (en) * 2012-12-06 2014-06-12 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
WO2015180613A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2015180614A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2015180612A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds

Also Published As

Publication number Publication date
UA123330C2 (uk) 2021-03-17
US20190284177A1 (en) 2019-09-19
CA3030370A1 (en) 2018-01-18
US20200291010A1 (en) 2020-09-17
US10934282B2 (en) 2021-03-02
AU2017294969B2 (en) 2021-03-25
ZA201808436B (en) 2020-05-27
ES2834009T3 (es) 2021-06-16
SA519400868B1 (ar) 2022-06-13
MX383770B (es) 2025-03-14
PL3484880T3 (pl) 2021-04-06
IL264141B (en) 2021-09-30
PT3484880T (pt) 2020-12-07
RU2019103883A (ru) 2020-08-13
NZ749301A (en) 2021-03-26
US10662181B2 (en) 2020-05-26
EP3484880B1 (en) 2020-09-02
JP2019521137A (ja) 2019-07-25
JP7016344B2 (ja) 2022-02-04
IL264141A (en) 2019-02-28
MY196990A (en) 2023-05-17
SG11201811107WA (en) 2019-01-30
CN109476653A (zh) 2019-03-15
WO2018011201A1 (en) 2018-01-18
KR20190026872A (ko) 2019-03-13
CN109476653B (zh) 2022-04-22
RU2019103883A3 (cg-RX-API-DMAC7.html) 2020-09-23
BR112019000486A2 (pt) 2019-04-24
MX2019000361A (es) 2019-05-23
EP3484880A1 (en) 2019-05-22
AU2017294969A1 (en) 2019-01-17
KR102490140B1 (ko) 2023-01-19
DK3484880T3 (da) 2020-11-09

Similar Documents

Publication Publication Date Title
US10513515B2 (en) Ether compounds and uses thereof
EP3022202B1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
CA2829188C (en) Dispiropyrrolidine derivatives
JP5016666B2 (ja) ケモカイン受容体のジアゼパン誘導体モジュレーター
EA031223B1 (ru) Соединения, которые ингибируют белок mcl-1
WO2013053051A1 (en) Indazole compounds as kinase inhibitors and method of treating cancer with same
SK8442000A3 (en) Hetorocyclic compounds, method for the preparation thereof, pharmaceutical composition comprising the same and their use
JP2008201787A (ja) ピペリジン置換体
JP2024516633A (ja) オレキシン-2受容体アゴニスト活性を有する置換されるアミド大環状化合物
US10934282B2 (en) Heteroaromatic modulators of the retinoid-related orphan receptor gamma
JP5389917B2 (ja) ケモカインレセプターのジアゼパン及びピペラジン誘導体モデュレーター
JP2023508955A (ja) 脂質異常症の治療に適した新規な化合物
US10494363B2 (en) Non-steroidal glucocorticoid receptor modulators for local drug delivery
HK40005345A (en) Heteroaromatic modulators of the retinoid-related orphan receptor gamma
NZ749301B2 (en) Heteroaromatic modulators of the retinoid-related orphan receptor gamma
WO2012115097A1 (ja) グリシントランスポーター阻害物質
NZ614321B2 (en) Glycine transporter-inhibiting substances